<SEC-DOCUMENT>0001070081-25-000011.txt : 20250227
<SEC-HEADER>0001070081-25-000011.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227161037
ACCESSION NUMBER:		0001070081-25-000011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250227
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		25678823

	BUSINESS ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20250227x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 2/27/2025 5:41:20 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: fa1bcb82-898e-4e38-8843-d545ba5b0cd6 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20250227" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>PTC THERAPEUTICS, INC._February 27, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityCentralIndexKey" id="Tc_QHkBzE9wfUemAo8yghH1iw_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:AmendmentFlag" id="Tc_LThLTeNxh02dsRlajrrl1w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20250227.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-27</xbrli:startDate><xbrli:endDate>2025-02-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_96648a38_c0f7_4684_b696_b5d7445d59a6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:DocumentType" id="Narr_KNnTlPzPHkCQgg7ng0q_wg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_SewdDztj4k-ayqvObCVHaA"><b style="font-size:9pt;font-weight:bold;">February 27, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityRegistrantName" id="Narr_HF4-lkpUkU60A3iKORVbGw"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_WmksASQ4aUKQQonMneej5w_2_0"></a><a id="Tc_anxNuUaAVkK9AyhDetnYpw_2_2"></a><a id="Tc_z0Z3xu0MoUy2nH_ExN--og_2_4"></a><a id="Tc_dxa5on2Tf0OBDVRZHZWgpA_3_0"></a><a id="Tc_tFff20FTVEKyR17ZA8TyFg_3_2"></a><a id="Tc_irkPzf3kTUW5vsDpSkPQHg_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_S7wBA20ZIEeTc8NiJvBQ4g_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityFileNumber" id="Tc_pWADQCgr0k679vzNaeGB1g_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityTaxIdentificationNumber" id="Tc_HX_IdFs_DkiXrje6O-iFzg_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_s5KvrxR6nkCiCuxaVeSxrg_2_0"></a><a id="Tc_f936dmitg0-yPYdhbosMeg_3_0"></a><a id="Tc_cihv7DEKS0yHbZWvlQ8aDw_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityAddressAddressLine1" id="Tc_oQymCZP2hkqmCpP1ttofIQ_1_0"><b style="font-size:9pt;font-weight:bold;">500 Warren Corporate Center Drive</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityAddressCityOrTown" id="Narr_S5lssFAOJ0iywKv4FCFq2w"><b style="font-size:9pt;font-weight:bold;">Warren</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityAddressStateOrProvince" id="Narr_6hWh7sU6IUCgH8DoeJwXZw"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:EntityAddressPostalZipCode" id="Tc_gjSB9NpfP0udCYdJkJErdg_2_3"><b style="font-size:9pt;font-weight:bold;">07059</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:CityAreaCode" id="Narr_YNX-JPnMFkiEYF3GCL_2HQ"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:LocalPhoneNumber" id="Narr_zL-C-Mpq70KWzGDj54c4qQ"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_3O5KZItkC0eI22FOMfAkjA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_65nlH3t5FU6OQwd_4s53cA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_LMr3Vik7ekGSTd1mWsyJXQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_ofQkAzjwSUKprYczOq8_Sw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_uczpzYPzCUG-sGV1EAWU6Q_1_0"></a><a id="Tc_YnBfBUSSTkCY_dursWtUkQ_1_2"></a><a id="Tc_JzZiDFJ1FUOG1A8ijytSuQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:Security12bTitle" id="Tc_A1s2XdZ9wEeO1AsYhiQYvw_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" name="dei:TradingSymbol" id="Tc_5c_wwOPRGEevQCb5s4rRDg_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_0fTE0sU-5UeFMCfO5Wz4sA_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_IEpnxlIiW0-4CD7Yd4Fgpg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b3891bd9_2b5c_4007_8beb_ab1bff61963a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;2.02.&#160;Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">On February 27, 2025, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and fiscal year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.</span></p><a id="_ef00b37e_0b0d_46b9_95e8_1011d7b7e5f4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7.01.&#160;Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Company will host a conference call on February 27, 2025 at 4:30 p.m. eastern time, as previously announced. During this call the Company expects to review financial results for the quarter and fiscal year ended December 31, 2024, as well as other corporate highlights and updates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></p><a id="_28ab756a_ea8c_4351_94df_735dd5a3f688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250227xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated February 27, 2025 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e8cf83be_f354_496a_84d0_eb6891fd4fb5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 27, 2025</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20250227xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/27/2025 05:41:19 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="display:inline-block;width:206.21pt;"></font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides Corporate Update and </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reports Fourth Quarter and Full Year 2024 Financial Results</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Full year 2024 revenue of $807 million, exceeding guidance &#8211; </i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing &#8211;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; License and collaboration agreement with Novartis for PTC518 Huntington&#8217;s disease program closed in January 2025 &#8211;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Cash of over $2.0 billion as of January 2025 &#8211;</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">WARREN, N.J., February 27, 2025</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024.&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;"><a name="_Hlk191477212"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;Our strong fourth quarter rounds out a year of significant accomplishment across every part of our company,&#8221; said Matthew B. Klein, M.D., Chief Executive Officer. &#8220;In 2024, our commercial team delivered another outstanding performance, we achieved all clinical and regulatory milestones on schedule and we solidified our balance sheet. We now have over $2 billion in cash to support our planned commercial and R&amp;D activities in 2025 and beyond. With the many accomplishments of 2024 and our team&#8217;s demonstrated ability to execute across every part of the business, we have built a strong foundation for continued success.</font><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;&#160;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Corporate Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fourth quarter 2024 total revenue of $213 million</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fourth quarter 2024 revenue for the DMD franchise of $144 million, including net product revenue for Translarna</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#8482;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of $94 million and for Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of $50 million</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Sold Rare Disease PRV received with FDA approval of Kebilidi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#8482;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> for $150 million</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">License and collaboration agreement signed with Novartis for PTC518 Huntington&#8217;s disease program, closed in January 2025</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 40.5pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Clinical and Regulatory Milestones:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC submitted four regulatory approval applications to FDA in 2024, all of which have been accepted for review:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of AADC deficiency in the U.S., approved in November 2024</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Sepiapterin for children and adults with PKU, with a target regulatory action date of July 29, 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Vatiquinone for children and adults with Friedreich&#8217;s ataxia, granted priority review with a target regulatory action date of August 19, 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Translarna for nmDMD</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC submitted several additional marketing authorization applications outside the U.S. for sepiapterin in 2024, with</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHMP opinion on sepiapterin MAA expected in Q2 2025 and a regulatory decision in Japan expected in Q4 2025. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Type C meeting with FDA held in December 2024 to discuss HTT lowering as potential surrogate endpoint to support accelerated approval for PTC518 for HD. The Agency was aligned with the scientific rationale for HTT lowering as a potential surrogate endpoint and asked that PTC provide </font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional clinical data, such as those being collected in PIVOT-HD, to show associations between HTT lowering and changes in clinical outcome measures. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">12-month results from the PIVOT-HD Phase 2 study of PTC518 expected in Q2 2025. </font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Fourth Quarter and Full Year 2024 Financial Highlights:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenues were $213.2 million for the fourth quarter of 2024, compared to $307.1 million for the fourth quarter of 2023. Total revenue was $806.8 million for full year 2024, compared to $937.8 million for full year 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenue includes net product revenue across the commercial portfolio of $154.7 million for the fourth quarter of 2024 and $601.0 million for full year 2024, compared to $155.1 million for the fourth quarter of 2023 and $661.2 million for full year 2023. Total revenue also includes royalty, collaboration, and manufacturing revenue of $58.5 million in the fourth quarter of 2024 and $205.8 million for full year 2024, compared to $152.0 million for the fourth quarter of 2023 and $276.6 million for full year 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Translarna net product revenues were $93.7 million for the fourth quarter of 2024, compared to $75.2 million for the fourth quarter of 2023. Translarna net product revenues were $339.9 million for full year 2024, compared to $355.8 million for full year 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Emflaza net product revenues were $50.5 million for the fourth quarter of 2024, compared to $67.4 million for the fourth quarter of 2023. Emflaza net product revenues were $207.2 million for full year 2024, compared to $255.1 million for full year 2023. These results were driven by the expiration of Emflaza&#8217;s orphan drug exclusivity in February 2024.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Roche reported Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> full year 2024 sales of approximately 1,631 CHF million, resulting in royalty revenue of $203.9 million to PTC for full year 2024, as compared to $168.9 million for full year 2023. Also in the fourth quarter of 2023, PTC recorded a sales milestone of $100.0 million for the achievement of $1.5 billion in worldwide annual net sales from Evrysdi. This sales milestone was recorded as collaboration revenue.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&amp;D expenses were $124.8 million for the fourth quarter of 2024, compared to $121.4 million for the fourth quarter of 2023. GAAP R&amp;D expenses were $534.5 million for full year 2024, compared to $666.6 million for full year 2023. The slight increase in R&amp;D expense for the fourth quarter of 2024 reflects additional costs due to manufacturing, regulatory filings, and inspections primarily related to </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Kebilidi </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">and sepiapterin. The decrease in R&amp;D expense for full year 2024 relates to decreases in program spend related to our strategic portfolio prioritization as we continue to focus our resources on our differentiated, high potential research and development programs. R&amp;D expense also included a total of $65.0 million regulatory success-based milestones paid to the former Censa securityholders for the year ended December 31, 2024, as compared to a $30.0 million success-based development milestone payable to the former Censa securityholders for the year ended December 31, 2023.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP R&amp;D expenses were $116.0 million for the fourth quarter of 2024, excluding $8.8 million in non-cash, stock-based compensation expense, compared to $113.2 million for the fourth quarter of 2023, excluding $8.1 million in non-cash, stock-based compensation expense. Non-GAAP R&amp;D expenses were $497.9 million for full year 2024, excluding $36.6 million in non-cash, stock-based compensation expense, compared to $613.6 million for full year 2023, excluding $52.9 million in non- cash, stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">GAAP SG&amp;A expenses were $84.7 million for the fourth quarter of 2024, compared to $76.3 million for the fourth quarter of 2023. GAAP SG&amp;A expenses were $300.9 million for full year 2024, compared to $332.5 million for full year 2023. The increase in SG&amp;A expense for the fourth quarter of 2024 reflects our continued investment to support commercial activities, including expanding our commercial portfolio. The decrease in SG&amp;A expense for full year 2024 was primarily due to lower employee costs as a result of the reduction in the workforce in 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP SG&amp;A expenses were $76.3 million for the fourth quarter of 2024, excluding $8.4 million in non-cash, stock-based compensation expense, compared to $67.9 million for the fourth quarter of 2023, excluding $8.4 million in non-cash, stock-based compensation expense. Non-GAAP SG&amp;A </font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses were $262.9 million for full year 2024, excluding $38.0 million in non-cash, stock-based compensation expense, compared to $283.8 million for full year 2023, excluding $48.7 million in non- cash, stock-based compensation expense. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The change in the fair value of deferred and contingent consideration was a gain of $10.2 million for the fourth quarter of 2024, compared to a gain of $2.7 million for the fourth quarter of 2023. Change in the fair value of deferred and contingent consideration was a gain of $4.5 million for full year 2024, compared to a gain of $127.7 million for full year 2023. The full year 2024 change is primarily related to the Company&#8217;s strategic portfolio prioritization and decision to discontinue its preclinical and early research programs in its gene therapy platform in May 2023, which included programs for FA and Angelman syndrome. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The intangible asset impairment was $159.5 million for the fourth quarter and full year 2024, compared to $0.0 million for fourth quarter and $217.8 million for the full year 2023, which represented a non-cash charge. For the fourth quarter and full year 2024, we impaired $159.5 million related to a decrease in projected cash flows due to refinements in current market assumptions and the timing of patient treatments for AADC. For the full year 2023, we fully impaired the FA and Angelman syndrome intangible assets and recorded impairment expense of $217.8 million. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net loss was $65.9 million for the fourth quarter of 2024, compared to net loss of $155.8 million for the fourth quarter of 2023. Net loss was $363.3 million for full year 2024, compared to net loss of $626.6 million for full year 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities was $1,139.7 million on December 31, 2024, compared to $876.7 million on December 31, 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares issued and outstanding as of December 31, 2024, were 77,704,188.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Full Year 2025 Financial Guidance:&#160;</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates total revenues for full year 2025 to be between $600 million and $800 million, including in-line products, potential new product launches, and royalty revenue from Evrysdi.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates GAAP R&amp;D and SG&amp;A expenses for full year 2025 to be between $805 million and $835 million.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates non-GAAP R&amp;D and SG&amp;A expenses for full year 2025 to be between $730 million and $760 million, excluding estimated non-cash, stock-based compensation expense of $75 million.&#160;</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:&#160;</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&amp;D and SG&amp;A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.&#160;&#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b><font style="font-size:11pt;"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consolidated Statements of Operations&#160;</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">(In thousands, except share and per share data)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:middle;width:23.22%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Three Months Ended December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:middle;width:21.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Twelve Months Ended December 31,</b></p></td></tr><tr><td style="vertical-align:middle;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Revenues:</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net product revenue</font></p></td><td style="vertical-align:middle;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 154,706</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 155,062</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 600,951</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 661,249</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Collaboration revenue</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 304</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 100,024</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 304</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 100,030</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Royalty revenue</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 58,162</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 50,999</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 203,864</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 168,856</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Manufacturing revenue</font></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 971</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,661</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 7,687</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total revenues</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 213,172</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 307,056</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 806,780</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 937,822</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Operating expenses:</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Cost of product sales, excluding amortization of acquired intangible assets</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 16,283</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 29,118</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 57,398</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 65,486</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Amortization of acquired intangible asset</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 3,307</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 77,174</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 60,738</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 222,635</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Research and development (1)</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 124,770</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 121,353</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 534,480</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 666,563</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Selling, general and administrative (2)</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 84,683</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,291</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 300,911</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 332,540</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Change in the fair value of contingent consideration</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (10,175)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (2,700)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (4,475)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (127,700)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Intangible asset impairment </font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 159,548</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 159,548</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 217,800</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Tangible asset impairment and losses (gains) on transactions, net</font></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (2,855)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 750</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total operating expenses</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 375,561</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 301,236</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,109,350</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,377,324</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">(Loss) income from operations</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (162,389)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 5,820</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (302,570)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (439,502)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Interest expense, net</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (41,060)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (44,274)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (166,993)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (129,180)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Other income, net</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,850</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 18,961</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 6,544</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 10,130</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Gain on Sale of priority review voucher</font></p></td><td style="vertical-align:middle;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 99,900</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 99,900</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Loss on extinguishment of debt</font></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (137,558)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (137,558)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Loss before income tax benefit (expense)</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (94,699)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (157,051)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (363,119)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (696,110)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Income tax benefit (expense)</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 28,813</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,259</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (176)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 69,506</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net loss attributable to common stockholders</font></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (65,886)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (155,792)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (363,295)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (626,604)</font></p></td></tr><tr><td style="vertical-align:middle;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Weighted-average shares outstanding:</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Basic and diluted (in shares)</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 77,201,783</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 75,490,569</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,845,055</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 74,838,392</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</font></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (0.85)</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (2.06)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (4.73)</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (8.37)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(1) Research and development reconciliation</b></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP research and development</font></p></td><td style="vertical-align:middle;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 124,770</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 121,353</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 534,480</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 666,563</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,818</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,113</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 36,629</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 52,941</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP research and development</b></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 115,952</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 113,240</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 497,851</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 613,622</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</b></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP selling, general and administrative</font></p></td><td style="vertical-align:middle;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 84,683</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,291</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 300,911</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 332,540</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,420</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,395</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 37,986</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 48,695</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP selling, general and administrative </b></p></td><td style="vertical-align:middle;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,263</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 67,896</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 262,925</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.28;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 283,845</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:54.07%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Summary Consolidated Balance Sheets&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">(in thousands, except share data)</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:11.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:10.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.82%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.05%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and marketable securities</font></p></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 1,139,696</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 876,739</font></p></td></tr><tr style="height:18.85pt;"><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:middle;width:7.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;"> 1,705,024</b></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:10.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;">  1,895,698</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total debt</font></p></td><td style="vertical-align:middle;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 285,412</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 284,213</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total deferred revenue</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 5,505</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 801</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total liability for sale of future royalties</font></p></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 2,081,776</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 1,814,097</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:middle;width:7.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;"> 2,803,095</b></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:10.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;"> 2,714,253</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total stockholders&#39; deficit (77,704,188 and 75,708,889 common shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively)</font></p></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> (1,098,071)</font></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> (818,555)</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities and stockholders&#39; deficit</b></p></td><td style="vertical-align:middle;width:7.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;"> 1,705,024</b></p></td><td style="vertical-align:middle;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:10.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;">  1,895,698</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.89%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2025 R&amp;D and SG&amp;A Expense&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">(in millions)</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low End of Range</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.78%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High End of Range</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Projected GAAP R&amp;D and SG&amp;A Expense</font></p></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 805</font></p></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 835</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Less: projected non-cash, stock-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 75</font></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 75</font></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense </b></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 730</font></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.03%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.74%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 760</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Acronyms:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">AADC: Aromatic L-Amino Acid Decarboxylase</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHF: Confoederatio Helvetica Francs (Swiss francs)</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHMP: Committee for Medicinal Products for Human Use</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DMD: Duchenne Muscular Dystrophy</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FA: Friedreich&#8217;s Ataxia</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FDA: U.S. Food and Drug Administration</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP: Generally Accepted Accounting Principles</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HD: Huntington&#8217;s Disease</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HTT: Huntingtin </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">MAA: Marketing Authorization Application</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NDA: New Drug Application</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">nmDMD: Nonsense mutation Duchenne muscular dystrophy</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PKU: Phenylketonuria</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PRV: Priority Review Voucher</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">R&amp;D: Research and Development</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SG&amp;A: Selling, General, and Administrative</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#39;s Conference Call and Webcast Reminder: </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">To access the call by phone, please </font><font style="font-family:'Arial','Helvetica','sans-serif';">click here</font><font style="font-family:'Arial','Helvetica','sans-serif';"> to register and yo</font><font style="font-family:'Arial','Helvetica','sans-serif';">u will b</font><font style="font-family:'Arial','Helvetica','sans-serif';">e provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://ir.ptcbio.com/events-presentations</font><font style="font-family:'Arial','Helvetica','sans-serif';">. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> and follow us on Facebook, X, and LinkedIn.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors:</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Ellen Cavaleri</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (615) 618-6228</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">ecavaleri@ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media:</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">fact, are forward-looking statements, including the information provided under the heading &quot;PTC Full Year 2025 Financial Guidance&quot;, including with respect to (i) 2025 total revenue guidance and (ii) 2025 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance,&quot; &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Commission adopts the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for the conditional marketing authorization for Translarna in the EEA, or PTC&#39;s ability to identify other potential mechanisms by which it may provide Translarna to nmDMD patients in the EEA; PTC&#39;s ability to use the clinical data from its international drug registry study and real-world evidence concerning Translarna&#39;s benefits to support a continued marketing authorization for Translarna for the treatment of nmDMD in the EEA; PTC&#39;s ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC&#39;s interpretation of the results of clinical trials and the totality of clinical data from its trials in Translarna; expectations with respect to PTC&#39;s license and collaboration agreement with Novartis Pharmaceuticals Corporation including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to sepiapterin, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under PTC&#39;s SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; PTC&#39;s ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi, Waylivra, sepiapterin or vatiquinone.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20250227.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/27/2025 5:41:25 PM-->
<!--Modified on: 2/27/2025 5:41:25 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20250227" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20250227" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250227_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250227_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250227_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>tmb-20250227_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/27/2025 5:41:25 PM-->
<!--Modified on: 2/27/2025 5:41:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20250227.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>tmb-20250227_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/27/2025 5:41:25 PM-->
<!--Modified on: 2/27/2025 5:41:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>tmb-20250227_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/27/2025 5:41:25 PM-->
<!--Modified on: 2/27/2025 5:41:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20250227.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638762748858530796" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638762748858530796" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638762748858530796" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638762748858530796" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638762748858530796" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638762748858530796" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638762748858530796" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638762748858530796" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638762748858530796" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638762748858530796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638762748858530796" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638762748858541428" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638762748858541428" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638762748858541428" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638762748858541428" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638762748858541428" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638762748858541428" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638762748858541428" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638762748858541428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638762748858541428" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638762748858551231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638762748858551231" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638762748858551231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638762748858551231" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638762748858551231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638762748858551231" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638762748858551231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638762748858551231" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45343361955168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 27,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Warren Corporate Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;%!+ 0(4 Q0    ( %&!6UHJ4(A7[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %&!6UJ97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ 48%;6JI/- -6!   OA   !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %&!6UJ?H!OPL0(  .(,
M   -              "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M48%;6I>*NQS     $P(   L              ( !=@\  %]R96QS+RYR96QS
M4$L! A0#%     @ 48%;6APX9>H_ 0  / (   \              ( !7Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %&!6UHD'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( %&!6UIED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20250227x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20250227.xsd</File>
    <File>tmb-20250227_def.xml</File>
    <File>tmb-20250227_lab.xml</File>
    <File>tmb-20250227_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20250227x8k.htm">tmb-20250227x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20250227x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20250227",
   "dts": {
    "schema": {
     "local": [
      "tmb-20250227.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20250227_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20250227_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20250227_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20250227x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250227x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250227x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001070081-25-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-25-000011-xbrl.zip
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M;&WV*MFS6>U[D&P]"$?_ %!+ P04    " !1@5M:X4_2V;(%  "B0   %
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MQ;B[I!DKT83E@FZ294YQ7Z)6;B#MUCBZ\E\Z?A!7-V_T)UG;F_\!4$L#!!0
M   ( %&!6UJ\N'JL<00  +8E   4    =&UB+3(P,C4P,C(W7W!R92YX;6S5
M6EV/VC@4?1]I_X,W^YQ/8/@04#%TND(=.FB@:K4OE4D,6)O8D6,&^/=KAWA*
M0@*9U6YH7DB(CZ_//<<XO@G]#_O !Z^(19B2@68;E@80<:F'R7J@;?E*[V@?
MAK_=]7_7]>\/+T_ H^XV0(0#ER'(D0=VF&_ @H8A)&"*&,.^#QX8]M8( -LR
MNH9E-("N#^,0#S 272@!<2S'L%7#.(E&20\XIM,V'<MI@5:O:??$<395N*E@
MML+7@#XF?_?DQU*,!T2&).KM(SS0-IR'/=/<[7;&KF%0MA;=+=O\/GV:NQL4
M0!V3B$/B(@T(?"^*+SY1%_)8GI/N^R7S58"&^396(4)^TQ5,EY=TV]$;MK&/
M/"VA*)M+#*+@LA5?P)_D<L2?Q4\TL+O=KAFW:L,[ /J,^N@%K4!\J<</(1IH
M$0Y"7X:*KVT86@TT'BQU*;_E.&V9QQ\?D\FACB/B/1*.^6%"5I0%L8H:D.&_
MODQ23$+N+C$U7!J8LMDL%RG.JY1B9IQ8R% D@L6]GT1;DHT<\;]@<R(7VG-$
M/.2]7<5<CF%95M<".E"!3D\A\< Q*OAW2<H419(^=5-4?#E]*4M;)Z-%(EP<
M*D*NL::OIH>P_#DUY8DTMAF;*K[\&%.Q1(R6$6?0Y2J2#Y?('VB9-O-_I*&T
M6HB(&1;9YA_WC4[[WFDW.YU6I]6PVMW[G]Q.Y\&(I7E"YJK0XO1L:J2U3Q!F
M")F(I[L;[+]9OF(T.%,G&8F6)$R9AYA8EC6PC00/&DK&T*]&Y1EBF(J)[GT4
M2_,%N5.X6NE^G7EB@%.I <=5X!/VT9=ML$0L1_LLI!:RER*=*-ZX@>(O:(TE
M<\*_P"!OQN?!:J1\">*)^LT;J#\1VTX64A:+-1>:H3'=$LX.8^H5FW&Q5XV\
M>7\>B56M&UBU@/N))W(56_'CUOC*.E6 KY$][\D@,>;^!L:,/$_(%B4'L<5%
M=J$I.=@:&5*6?6)&^W9FC,7I,UO0';EFQ4]D_8RXPCVQH7,[&^(U]9G-&'W%
MQZ+XHA<9>/T,*9- XDKW=J[,:,2A_Q<.+][D\\#U<^0Z?57N694:(G^Z(X9@
M@06GS6G63;OI='X]T:\25C)76U;+QXC^;$-)<567A=1"[E*DE>35%M+?&.8<
MD3$-@BU)-FY1CNZYN%J(7YZY<J#:PGI.?>QBCLEZ*FY'#,OQSN0_!]5"^Y*T
ME?#5UM0SAN2D0.+6'S]AE$^CV?-JE;ON%(-K8<0[Z2M#JJV<,R0G4;1%[%VV
MG'6IHSGEDE 655M#SY&[%>OIP7:6"_F^)F^IRD!J84$ITDKR:BOE!8/R5?/\
M$"QIWJTAU5X+L:\S5DI76PRK2?"X=S>0K%'!(^X\6#J+ENTT[%]/]]+$E?RW
MJ'H? \368G;\R>B.;\2Z&$)R*"Q[<]&U,..]_-5KMFH+WR/+L4B007\B[DC[
MSZC8C0RN1CZ48:X<J+8F'HDM@2>W!9]\N,Y1/M5>"\6O,U9*%Y3"?3/[+Y7A
M7=\\"H./__08_@-02P,$%     @ 48%;6D5:11+R%@  T:\  !,   !T;6(M
M,C R-3 R,C=X.&LN:'1M[3WI=]J^LM_O7Z&7W[NWZ7DQ>&5+FGL(2T+3  FD
M:?O%1[9E<#&V:YL ^>O?2+;9DY(&LC3TG+;8DJ71K)K12#KZ[ZAOHUOB!Y;K
M?/H@I/@/B#BZ:UA.Y].'8JM4JWWX[_&_COZ'XY#U[>3J"S)<?= G3HATG^"0
M&&AHA=T":KN>AQUT07S?LFUTXEM&A\2?"'PJG^)3$N*XN*D3',"7KE-(:J2$
M:6$I;I@6BVDQFQ9Y44%*018*(H^:%].:T<=?+,W'_C@910%:@P[YC)@2,K(H
M+59O$?_6T@GZ[&JH5BX@$PN:KN5$+I?/$4XF4H[+Y62),Q19T;"B\;J1B=KH
MAH KP)<3% QB?=KKAJ%72*='FF^G J*G.NYM&@HHO/)>5'%2:3@<IH92RO4[
M:2&?SZ='M+&X4L&VG-Y<3=8DK2ORO)2FQ1I@+*D^6JH_US(MG52%AHQP'M2X
M724=%4ZJK@06*@KI;Q=?6GJ7]#%G.4&('7T"BC4*.1CZW)<)*BP'("$4Y^G0
MQTY@NGX?AT A:%10.#['24+2CA?JX5PC\$*SW)3N]AGY>5',SO2Y&ED/=2B*
M'"]R0F;:R'T(%Z29AI+J/C'O)5 F#:6S"+<>H.4$@<='78*-XZ,^"3&BU3GR
M:V#=?MK372<$^>+"L0=HCI\^[85D%*89TZ2/CT(KM,EQLUU"[;/*5;%9N6[7
M2JT#5*N74FJ5:/Z "H28/4 4>4?IJ/Y1.NI2<XWQ\9%AW:(@'-ODTUX?^QW+
MX4+7*TB\%QX"<&DHGJMC6(%GXW'!<1U"*UBC FV-^-%/RS"(PWY"A3IH"-_2
M(^!'X15%7GG@,UJHHBIF50J6VG9G'JKZUY-3=9R_XT^OE)\>U^UKH];E'G)P
MG_9.K$+%@6&,2X -']LUQR"C<S+>0Y;Q::^MJY=GO9.[2GYH7I-^T<V-.]TS
MP1I"!\+>,0],S&=Y/B<<I><@W"[ 1="3!M6551MW)H!^:7>_M$E]U.5%([BR
M\4_?MX6A*E% 36P'9 G&]#R"@=N(#TJ:!,='5-8+ 9-- !HQV2]T&;>&?8U+
M1"<U"HR]N)3RU:>]P.I[-J&\E%YHDCT&[L!G3XR?"S%>V!#^$"])4X11,7FR
M#/IL6L1';!1DI28IU<[GB;CX\7'R:KYU#_#G&LD3")X?EL&T'%,XJ3H0L\EW
MT[()F,8]59.2Y#GI)#V'J@2O$T2F9P1F2;CZ>,0-+0,,J<#S_S[TL$$-,&<3
M,X0W*4F9OO.M3G?ZT@TL2@OHR :BW#+)G&E7MPGV"YH;=@]C&6=-<O YE?/X
M7=3D].4\+$M=1(4ZMO5]6@/]'R@9^N7'A<X71@%-+XZ!OKJG>=8WM.<EK9F
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M@7 UL$DDK+*HQ'*U<.P!/>U@7\BB4O4*B1*?@HH?7]/,;R<:6Q.-E@NJ$KC
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MU8B3Y.?B&O/OZ'8/*>*QQ03_6]<R5N?W3Q+XTYIKC.&_;MBWC_\?4$L#!!0
M   ( %&!6UK"S":8!30  $P1 P 7    =&UB+3(P,C4P,C(W>&5X.3ED,2YH
M=&WM??MWVS;R[[^"F\UVG7-IA:3>3C?G>IVDZ;;)9I-T]WY_N@<B(0D-1:H
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M^'K>?,CE.**3*QZK5GI1$GPS0_'=5LWW#)7P'2#H\E$)3J._.7][SZ);EO*
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M*G&8>?3L];NR+E=RGR:ILN*SJ(7OU?.HQ91E<!8OD<0OU9I8!K(,Q.8"7CD
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MQ8#>U.S#+Q%TB5I+8J0+,0'/HXNE?5@=U6(L+F_&@B?#V=W5^=I&_;5FPR1
ME7F@--8;6 0.;B1PYT'X,*D6!^9PDERPB(9)0 <L9H1]S\94W":W++A,8_;'
M"Z(>IVJK9C+UJE/,^E,6%!CP^OK-#0E9GP><Q<$$&12_\UOM2\TQK*SM(UA8
MO>V"_&M9TK+DO%?$QIR"ZA+<A.&'/ H%TR$&&JJ-/075/OWRFZ-_HR2%96%I
M27L&"N6IW4'<<<XB@&1=YQY89KGN3+GN/V!>_\AX#"AO/=>] ZK !V!MI\X
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M%ZTZ"06'/DEOH@8+[C(WR=,P4#/$:19$(L9#&L,KV0#K"D69Q / *A%L5D$
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M@:Z.@P]"WN\#=V/2"/3BD"%,OI!& M^'\>(>* PE!,4?)6-E<\P@96UAIL7
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ME'!@?R[T=4.8->\UN_?G8:F:Q.N"+_/I!4O>?P[RMFP#=LXX:]87;(SRHXK
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MKS @,5>BZ!V/::R\S9\R'L*O3'^UV(\. ^A[(] +O> O],NI*M%MKB\G ].
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M*$#3B@<IOP[7;<<4MEI1<:I%,,G$!8.&)U0P:PTH3&7NUZ*9U+\O;!^CKD8
M'":@>>,DU38!,_K4ZD54I35J2ZL1X*W.(IP8N[=ZO,K1[$>(9,M!5VRG !G5
M3HHSVT9!.R^ST=@ QCR,GL<;?]<(0BKVTO8[X"+(1GA'.4*E) @RH5U4E=I\
M#P78=SRVB-02 *2XT,$/0*XU:V<>9&=V-RIXC. ^F_*REX03^#%,1]'K_P]0
M2P$"% ,4    " !1@5M:MW B!]@#  "&#P  $               @ $
M=&UB+3(P,C4P,C(W+GAS9%!+ 0(4 Q0    ( %&!6UKZN?:WX (  /4*   4
M              "  08$  !T;6(M,C R-3 R,C=?9&5F+GAM;%!+ 0(4 Q0
M   ( %&!6UKA3]+9L@4  *)    4              "  1@'  !T;6(M,C R
M-3 R,C=?;&%B+GAM;%!+ 0(4 Q0    ( %&!6UJ\N'JL<00  +8E   4
M          "  ?P,  !T;6(M,C R-3 R,C=?<')E+GAM;%!+ 0(4 Q0    (
M %&!6UI%6D42\A8  -&O   3              "  9\1  !T;6(M,C R-3 R
M,C=X.&LN:'1M4$L! A0#%     @ 48%;6L+,)I@%-   3!$# !<
M     ( !PB@  '1M8BTR,#(U,#(R-WAE>#DY9#$N:'1M4$L%!@     &  8
*B@$  /Q<      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tmb-20250227x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20250227.xsd" xlink:type="simple"/>
    <context id="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2025-02-27</startDate>
            <endDate>2025-02-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_QHkBzE9wfUemAo8yghH1iw_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_LThLTeNxh02dsRlajrrl1w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_KNnTlPzPHkCQgg7ng0q_wg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_SewdDztj4k-ayqvObCVHaA">2025-02-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_HF4-lkpUkU60A3iKORVbGw">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_S7wBA20ZIEeTc8NiJvBQ4g_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_pWADQCgr0k679vzNaeGB1g_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_HX_IdFs_DkiXrje6O-iFzg_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_oQymCZP2hkqmCpP1ttofIQ_1_0">500 Warren Corporate Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_S5lssFAOJ0iywKv4FCFq2w">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_6hWh7sU6IUCgH8DoeJwXZw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_gjSB9NpfP0udCYdJkJErdg_2_3">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_YNX-JPnMFkiEYF3GCL_2HQ">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_zL-C-Mpq70KWzGDj54c4qQ">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_3O5KZItkC0eI22FOMfAkjA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_65nlH3t5FU6OQwd_4s53cA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_LMr3Vik7ekGSTd1mWsyJXQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_ofQkAzjwSUKprYczOq8_Sw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_A1s2XdZ9wEeO1AsYhiQYvw_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_5c_wwOPRGEevQCb5s4rRDg_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Tc_0fTE0sU-5UeFMCfO5Wz4sA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_27_2025_To_2_27_2025_FcVBG_y9z0GR5jp-hmbxSQ"
      id="Narr_IEpnxlIiW0-4CD7Yd4Fgpg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
